1. Volume 150, Issue 3, Pages 533-543 (September 2016)
Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis 
Anna Serrano-Mollar, PhD, Gemma Gay-Jordi, PhD, Raquel Guillamat-Prats, PhD, Daniel Closa, PhD, Fernanda Hernandez-Gonzalez, MD, Pedro Marin, PhD, Felip Burgos, PhD, Jaume Martorell, PhD, Marcelo Sánchez, MD, Pedro Arguis, MD, Dolors Soy, PhD, José M. Bayas, PhD, José Ramirez, PhD, Teresa D. Tetley, PhD, Laureano Molins, PhD, Jordi Puig de la Bellacasa, PhD, Camino Rodríguez- Villar, PhD, Irene Rovira, PhD, Juan José Fiblà, MD, Antoni Xaubet, PhD 
CHEST 
Volume 150, Issue 3, Pages (September 2016)
DOI: /j.chest
Copyright © 2016 American College of Chest Physicians Terms and Conditions

2. Figure 1
Clinical study flow diagram. 6MWT = 6-min walk test; Dlco = single-breath diffusing capacity for carbon monoxide; HRCT = high-resolution computed tomography; IPF = idiopathic pulmonary fibrosis.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

3. Figure 2
Alveolar type II (ATII) cells. A, Cytospin preparation showing alkaline phosphatase–positive ATII cells (red), original magnification ×200. B and C, Transmission electron micrographs of ATII cells (arrows) showing lamellar bodies. D, Detail of ATII cell. E, Detail of the lamellar bodies. F, Representative histogram of flow cytometry analysis of CD32 in isolated cells. Cells were immunostained with PE-labeled anti-CD32 antibody to evaluate the macrophage population in the isolated cells. G, Representative histogram of flow cytometry analysis of p180 lamellar body in isolated cells. Cells were immunostained with PE-labeled anti-p180 lamellar body antibody to evaluate ATII in the isolated cells. PE = phycoerythrin.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

4. Figure 3
Changes from baseline at diagnosis to 12 months in all the study patients. Data in graph represent individual data points and means (black squares). Solid line represents patients who remained stable (n = 13); dotted line represents patients with deterioration of disease (n = 3). A, FVC (%); B, Dlco (%); C, 6MWT distance (m); D, Sao2 initial (6MWT); E, Sao2 final (6MWT); F, score of overall extent of disease in HRCT. See Figure 1 legend for expansion of abbreviations.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions

5. Figure 4
High-resolution computed tomography (HRCT). A and B, Representative HRCT images from two different patients of the 13 patients who remained stable at baseline and after 12 months of follow-up. No changes were observed in the disease extent between baseline and 12 months of follow-up.
CHEST  , DOI: ( /j.chest )
Copyright © 2016 American College of Chest Physicians Terms and Conditions